Full text is available at the source.
Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy
Using Nanomedicine to Improve Chemotherapy Drugs for Glioblastoma in Patients and Clinical Trials
AI simplified
Abstract
Glioblastoma multiforme has the lowest median overall survival among all malignant brain tumors.
- Current therapeutic strategies for glioblastoma are insufficient, necessitating novel approaches.
- Nanomedicine may enhance drug delivery to the brain, improving treatment outcomes.
- This review focuses on nanomedicine-based delivery strategies tested in animal models.
- Drug candidates currently in clinical use or trials may benefit from these nanotechnology approaches.
- Future perspectives suggest that nanocarriers could play a significant role in glioblastoma treatment.
AI simplified